Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis

References

• Mahindra A, Hideshima T, Anderson KC. Multiple myeloma: biology of the disease. Blood Rev 2010;24(Suppl. 1):S5–S11.
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Cook G. Immunotherapy in multiple myeloma--possibility or probability?. Br J Haematol 2005;130:344–362.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118–1122.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1782–1791.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366:1770–1781.
   PubMed Web of Science ®Google Scholar
• Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007;104:11406–11411.
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34 + progenitor cells. Cancer Res 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010;10:155–167.
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266–1273.
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20 + tumor cells. Clin Cancer Res 2008;14:4650–4657.
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380–386.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Kovarova L, Hajek R. Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma. Leuk Lymphoma 2012;53:1406–1408.
   PubMed Web of Science ®Google Scholar
• Minnema MC, van der Veer MS, Aarts T, et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 + Foxp3 + T cells. Leukemia 2009;23:605–607.
   PubMed Web of Science ®Google Scholar
• Clave E, Busson M, Douay C, et al. Acute graft versus host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009;113:6477–6484.
   PubMed Web of Science ®Google Scholar
• Svaldi M, Lanthaler AJ, Dugas M, et al. T-cell receptor excision circles: a novel prognostic parameter for the outcome of transplantation in multiple myeloma patients. Br J Haematol 2003;122:795–801.
   PubMed Web of Science ®Google Scholar
• Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000;355:1875–1881.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708–712.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745–763.
   PubMed Web of Science ®Google Scholar
• Appay V, van Lier RA, Sallusto F, et al. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008;73:975–983.
   PubMed Web of Science ®Google Scholar
• Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol 2012;24:476–481.
   PubMed Web of Science ®Google Scholar
• Valmori D, Scheibenbogen C, Dutoit V, et al. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(+) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res 2002;62:1743–1750.
   PubMed Web of Science ®Google Scholar
• Goodyear OC, Pratt G, McLarnon A, et al. Differential pattern of CD4 + and CD8 + T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood 2008;112:3362–3372.
   PubMed Web of Science ®Google Scholar
• Neuber B, Herth I, Tolliver C, et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol 2011;187:1047–1056.
   PubMed Web of Science ®Google Scholar
• Champagne P, Ogg GS, King AS, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001;410:106–111.
   PubMed Web of Science ®Google Scholar
• Maldonado A, Mueller YM, Thomas P, et al. Decreased effector memory CD45RA + CD62L + CD8 + T cells and increased central memory CD45RA + CD62L + CD8 + T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res Ther 2003;5:R91–R96.
   Google Scholar
• Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3 + regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 2007;21:2512–2518.
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373–5380.
   PubMed Web of Science ®Google Scholar
• Miller AM, Lundberg K, Ozenci V, et al. CD4 +CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398–7405.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Kaminska W, Hus I, et al. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br J Cancer 2012;106:546–552.
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One 2012;7:e47077.
   PubMed Web of Science ®Google Scholar
• Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends Immunol 2013;34:33–40.
   Google Scholar
• Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One 2012;7:e35981.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4 + CD25high FoxP3 + regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940–3949.
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301–304.
   PubMed Web of Science ®Google Scholar
• Feyler S, von Lilienfeld-Toal M, Jarmin S, et al. CD4(+) CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(+)CD8(+)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009;144: 686–695.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Dmoszynska A, Rolinski J. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk Res 2007;31:411–412.
   PubMed Web of Science ®Google Scholar
• Lee BN, Gao H, Cohen EN, et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011;117:3999–4008.
   PubMed Web of Science ®Google Scholar
• Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood 2006;108:253–261.
   PubMed Web of Science ®Google Scholar
• Simonetta F, Gestermann N, Martinet KZ, et al. Interleukin-7 influences FOXP3 + CD4 + regulatory T cells peripheral homeostasis. PLoS One 2012;7:e36596.
   Google Scholar